Lombardo M, Fusco M, Valente D
G Ital Cardiol. 1979;9(12):1363-70.
Ten patients affected by essential moderate or severe hypertension were given five sequential treatments, each for three weeks: 1) placebo, 2) chlorthalidone (Cl) 100 mg daily, 3) Cl 50 mg + oxprenolol slow release (Ox) 160 mg daily, 4) Ox 160 mg and 5) Ox 320 mg daily. Four subjects poor responders (DPB greater than or equal to 110 mmHg) received a later administration of Ox 160 + Cl 50 + hydrallazine (Hydr) 25-100 mg daily. Both groups of patients showed the greatest antihypertensive action with Ox 160 + Cl 50 mg daily. Oxprenolol induced a similar hypotensive effectiveness at 160, as well as 320 mg/day. Relationship between plasma renin activity (PRA) values and antihypertensive response to each treatment takes the following conclusions: 1) Basal PRA levels cannot be a guide for preferential choice of diuretic or betablocking therapy. 2) It is likely that renin activated by Cl and Hydr partially blunts their hypotensive activity. On the contrary, essential hypertension with normal or low PRA does not seem depending on angiogensinogenic factors. 3) Oxprenolol remarkably inhibits the overreninism induced by chlorthalidone and hydrallazine, in such way increasing their antihypertensive action. 4) In the management of essential moderate or severe hypertension is preferable to employ a mild dosage of betablockers and diuretics, rather than use higher doses of a single agent.
10名患有原发性中度或重度高血压的患者接受了五种连续治疗,每种治疗为期三周:1)安慰剂,2)氯噻酮(Cl)每日100毫克,3)Cl 50毫克+氧烯洛尔缓释剂(Ox)每日160毫克,4)Ox 160毫克,5)Ox每日320毫克。4名反应不佳的受试者(舒张压大于或等于110毫米汞柱)随后接受了每日Ox 160 + Cl 50 +肼屈嗪(Hydr)25 - 100毫克的治疗。两组患者每日服用Ox 160 + Cl 50毫克时均显示出最大的降压作用。氧烯洛尔在每日160毫克以及320毫克时诱导出相似的降压效果。血浆肾素活性(PRA)值与每种治疗的降压反应之间的关系得出以下结论:1)基础PRA水平不能作为利尿剂或β受体阻滞剂治疗优先选择的指导。2)Cl和Hydr激活的肾素可能会部分减弱它们的降压活性。相反,PRA正常或较低的原发性高血压似乎不依赖于血管生成素生成因子。3)氧烯洛尔显著抑制氯噻酮和肼屈嗪诱导的肾素分泌过多,从而增强它们的降压作用。4)在原发性中度或重度高血压的治疗中,最好使用小剂量的β受体阻滞剂和利尿剂,而不是使用单一药物的高剂量。